Abstract: An object of the present invention is to provide an echinomycin derivative that has anti-cancer activity equal to or greater than that of echinomycin, and a production method therefor based on a chemical procedure. Provided are an echinomycin derivative represented by formula (I), and a production method therefor based on a chemical procedure.

Abstract: The invention relates to the field of biomedicine, in particular to the use of annexin A5 in the treatment of cerebral stroke. The invention provides a method for treating cerebral stroke and a drug combination containing annexin A5. The method can reduce cerebral infarction, improve symptoms of neurobehavioral deficits in the brain and treating stroke.

Abstract: A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.

Abstract: The invention is directed towards Apratyramide linear depsipeptide compounds, pharmaceutical compositions thereof, and methods of affecting wound healing, and methods of affecting the biological processes involved in wound healing (e.g., inflammation, cell proliferation, tissue granulation, remodeling of scar tissue, etc.).

Abstract: The present invention relates to polypeptides having myotoxin-neutralizing properties and their use for treatment of envenomation. The present invention further relates to methods for neutralizing a venom using the polypeptide of the invention as well as to methods of treatment of envenomation by administering said polypeptide to a subject in need thereof.

Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.

Abstract: Disclosed is a method of modulating the Sct/SR axis in a mammalian subject in need thereof, including in a subject suffering from a liver disease, such as but not limited to, Early Stage PBC, Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, Biliary Altresia, NASH, NAFLD, or Alcohol induced liver injury. A method of treating Late Stage PBC in a mammalian subject in need thereof is also disclosed; further disclosed is a method of ameliorating PBC-induced biliary damage in a mammalian subject in need thereof. Pharmaceutical compositions for modulating the Sct/SR axis, comprising a SR antagonist or a SR agonist, and a pharmaceutically acceptable carrier or excipient are also disclosed.

Abstract: Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin ?-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.

Abstract: The present invention relates to a peptide exhibiting physiological activities and a composition including the peptide. Because the peptide of the present invention exhibits various physiological activities such as muscle relaxation, skin wrinkle improvement, sebum production suppression, and the like, the peptide may be used as an active ingredient in a pharmaceutical composition for muscle relaxation, or cosmetics for improving skin wrinkles, suppressing sebum production, or ameliorating acne.

Abstract: Methods of purifying mucin, purified mucin, and products comprising the purified mucin. The methods include combining a mucin-containing substance with water and one or more purification agents to form a purification mixture, incubating the purification mixture for a time sufficient to form a mucin precipitate in a liquid phase, and separating the mucin precipitate from the liquid phase. The purification agents include one or more of a surfactant, a chelating agent, and a protic solvent. The mucin purified from the methods can be used alone or in combination with a biopolymer such as a tannin and chitosan and can be used to generate materials in the form of a gel, a foam, a film, or a powder.

Abstract: Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered.

Abstract: The present invention is directed to a composition that includes an amphiphile, its use in a method of preventing and/or treating cancer, and its use in a method of producing a pharmaceutical composition. In certain embodiments, the amphiphile includes a hydrophilic peptide that binds to a Plenty of SH3 domain (POSH) and inhibits or disrupts a POSH scaffold network, a hydrophobic moiety, and an aptamer. The present invention is also directed to other POSH inhibitor complex biomolecules that do not contain a hydrophobic moiety.

Abstract: Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient. The methods are particularly effective in improving urinary peak flow (Qmax), and in improving nocturia.

Abstract: The present invention provides novel GM-CSF constructs and methods of using the same. In certain embodiments, the constructs of the invention comprise certain peptide fragments from GM-CSF. In other embodiments, the invention provides certain GM-CSF peptides that act as GM-CSF mimetics.

Abstract: The invention features a compositions and methods for inducing an immune response to targeted cells. The compositions induce targeting of a cell by positioning carbohydrate epitopes on the surface of the cell by conjugation of the epitope to a pH-triggered membrane peptide (pHLIP®).

Abstract: The present invention provides prodrugs of somatostatin peptide and peptide analogs that are tissue permeable and oral bioavailable and enable activity of the somatostatin analog at the circulation or target tissue after cleavage of charge-masking lipophilic moieties. Pharmaceutical compositions comprising these prodrugs and their use in therapy and diagnosis are also provided.

Abstract: Provided are a repair peptide for use in promoting post-traumatic tissue repair and regeneration, and an application thereof. The repair peptide is a linear or cyclic peptide which is 4-15 amino acids in length and which contains four or more consecutive GPANVET core sequences.

Abstract: Aspects and embodiments of the present invention relate to the treatment of neurological disorders such as for example, Alzheimer's disease and Parkinson's disease. Particularly, certain embodiments relate to GIP/GLP-1 co-agonist peptides for use in the treatment of these two neurological disorders. Also included in the present invention are inter alia pharmaceutical compositions comprising the GIP/GLP-1 co-agonist peptides, together with methods of treating such disorders as well as other subject matter.

Abstract: The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.